Related Experiment Video
Updated: Jan 31, 2026

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
Published on: November 30, 2016
Toll-Like Receptor-4 Disruption Suppresses Adipose Tissue Remodeling and Increases Survival in Cancer Cachexia
Felipe Henriques1,2, Magno A Lopes1, Felipe O Franco1
1Integrated Group of Biotechnology, Laboratory of Adipose Tissue Biology, University of Mogi das Cruzes, São Paulo, Brazil.
Abstract:
Cancer-induced cachexia, characterized by systemic inflammation, body weight loss, adipose tissue (AT) remodeling and muscle wasting, is a malignant metabolic syndrome with undefined etiology. Here, we show that both genetic ablation and pharmacological inhibition of TLR4 were able to attenuate the main clinical markers of cachexia in mice bearing Lewis lung carcinoma (LLC). AT remodelling was not found in LLC tumor-bearing (TB) TLR4-/- mice due to reduced macrophage infiltration and adipocyte atrophy. TLR4-/- mice were also resistant to cold-induced browning of subcutaneous AT (scAT). Importantly, pharmacological inhibition of TLR4 (Atorvastatin) reproduced the main protective effect against AT remodeling found in TLR4-/- TB mice. Moreover, the treatment was effective in prolonging survival and attenuating tumor mass growth when compared to non-treated-TB animals. Furthermore, tumor-induced elevation of circulating pro-inflammatory cytokines was similarly abolished in both genetic ablation and pharmacological inhibition of TLR4. These data suggest that TLR4 is a critical mediator and a promising target for novel anti-cachexia therapies.
Insights
Toll-like receptor 4 (TLR4) inhibition mitigates cancer cachexia in mice. Blocking TLR4 reduces inflammation, body weight loss, and adipose tissue remodeling, offering a potential therapeutic target for this metabolic syndrome.
Area of Science:
- Oncology
- Immunology
- Metabolism
Background:
- Cancer-induced cachexia is a complex metabolic syndrome.
- It involves systemic inflammation, weight loss, and muscle wasting.
- The exact causes of cachexia remain unclear.
Purpose of the Study:
- To investigate the role of Toll-like receptor 4 (TLR4) in cancer cachexia.
- To evaluate the therapeutic potential of targeting TLR4.
Main Methods:
- Used Lewis lung carcinoma (LLC) mouse model.
- Genetic ablation of TLR4 (TLR4-/- mice).
- Pharmacological inhibition of TLR4 using Atorvastatin.
Main Results:
- TLR4 deficiency or inhibition attenuated cachexia markers.
- Reduced adipose tissue remodeling and macrophage infiltration in TLR4-/- mice.
- Atorvastatin treatment prolonged survival and reduced tumor mass.
- Blocked tumor-induced elevation of pro-inflammatory cytokines.
Conclusions:
- TLR4 is a key mediator in cancer cachexia development.
- Targeting TLR4 shows promise for novel anti-cachexia therapies.
Related Concept Videos
Cancer Survival Analysis
Nucleosome Remodeling
Nucleosome remodeling complex
Eukaryotic cells have specialized enzymes called ATP-dependent nucleosome remodeling enzymes. These enzymes...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Bone Remodeling
Survival Curves
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
Survival Tree
Building a Survival Tree
Constructing a...

